These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34943097)

  • 21. Soluble receptor for advanced glycation end products as a biomarker of symptomatic vasospasm in subarachnoid hemorrhage.
    Aida Y; Kamide T; Ishii H; Kitao Y; Uchiyama N; Nakada M; Hori O
    J Neurosurg; 2021 Jan; 134(1):122-130. PubMed ID: 31675694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes.
    Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Yasuda T; Umayahara Y; Kosugi K; Yamasaki Y
    Atherosclerosis; 2009 May; 204(1):288-92. PubMed ID: 18926539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).
    Lam JK; Wang Y; Shiu SW; Wong Y; Betteridge DJ; Tan KC
    Diabet Med; 2013 Jun; 30(6):702-9. PubMed ID: 23432638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of the receptor for advanced glycation end products system in women with severe preeclampsia.
    Oliver EA; Buhimschi CS; Dulay AT; Baumbusch MA; Abdel-Razeq SS; Lee SY; Zhao G; Jing S; Pettker CM; Buhimschi IA
    J Clin Endocrinol Metab; 2011 Mar; 96(3):689-98. PubMed ID: 21325454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Critical Appraisal of Advanced Glycation End Products (AGEs) and Circulating Soluble Receptors for Advanced Glycation End Products (sRAGE) as a Predictive Biomarkers for Cardiovascular Disease in Hemodialysis Patients.
    Assiri AMA; Kamel HFM; ALrefai AA
    Med Sci (Basel); 2018 May; 6(2):. PubMed ID: 29789493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic Derangements Contribute to Reduced sRAGE Isoforms in Subjects with Alzheimer's Disease.
    Fuller KNZ; Miranda ER; Thyfault JP; Morris JK; Haus JM
    Mediators Inflamm; 2018; 2018():2061376. PubMed ID: 29681765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study.
    Rebholz CM; Astor BC; Grams ME; Halushka MK; Lazo M; Hoogeveen RC; Ballantyne CM; Coresh J; Selvin E
    Nephrol Dial Transplant; 2015 Jan; 30(1):77-83. PubMed ID: 25147225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults.
    Palma-Duran SA; Kontogianni MD; Vlassopoulos A; Zhao S; Margariti A; Georgoulis M; Papatheodoridis G; Combet E
    Metabolism; 2018 Jun; 83():120-127. PubMed ID: 29409822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum levels of advanced glycation end products (AGEs) are increased and their soluble receptor (sRAGE) reduced in Hashimoto's thyroiditis.
    Ruggeri RM; Barbalace MC; Cristani MT; Alibrandi A; Giovinazzo S; Giuffrida G; Trimarchi F; Cannavò S; Campennì A
    J Endocrinol Invest; 2020 Sep; 43(9):1337-1342. PubMed ID: 32232775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients.
    Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Ueda Y; Suzuki T; Yamada S; Takeuchi M; Fukami K; Ueda S; Adachi H; Matsui T; Okuda S; Yamagishi S
    Metabolism; 2009 Nov; 58(11):1624-8. PubMed ID: 19604520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between Advanced Glycation End Products, Soluble RAGE Receptor, and Endothelium Dysfunction, Evaluated by Circulating Endothelial Cells and Endothelial Progenitor Cells in Patients with Mild and Resistant Hypertension.
    Gryszczyńska B; Budzyń M; Begier-Krasińska B; Osińska A; Boruczkowski M; Kaczmarek M; Bukowska A; Iskra M; Kasprzak MP
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of the Soluble Receptor for Advanced Glycation End Products (sRAGE) as a Prognostic Factor for Mortality in Hemodialysis and Peritoneal Dialysis Patients.
    Dozio E; Ambrogi F; de Cal M; Vianello E; Ronco C; Corsi Romanelli MM
    Mediators Inflamm; 2018; 2018():1347432. PubMed ID: 30410419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experimental Hyperglycemia Alters Circulating Concentrations and Renal Clearance of Oxidative and Advanced Glycation End Products in Healthy Obese Humans.
    Perkins RK; Miranda ER; Karstoft K; Beisswenger PJ; Solomon TPJ; Haus JM
    Nutrients; 2019 Mar; 11(3):. PubMed ID: 30823632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.
    Yamagishi S; Adachi H; Nakamura K; Matsui T; Jinnouchi Y; Takenaka K; Takeuchi M; Enomoto M; Furuki K; Hino A; Shigeto Y; Imaizumi T
    Metabolism; 2006 Sep; 55(9):1227-31. PubMed ID: 16919543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Receptor for advanced glycation end products--soluble form and gene polymorphisms in chronic haemodialysis patients.
    Kalousová M; Jáchymová M; Mestek O; Hodková M; Kazderová M; Tesar V; Zima T
    Nephrol Dial Transplant; 2007 Jul; 22(7):2020-6. PubMed ID: 17347281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of atorvastatin on progression of diabetic nephropathy and local RAGE and soluble RAGE expressions in rats.
    Lu L; Peng WH; Wang W; Wang LJ; Chen QJ; Shen WF
    J Zhejiang Univ Sci B; 2011 Aug; 12(8):652-9. PubMed ID: 21796806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cross-sectional Analysis of AGE-CML, sRAGE, and esRAGE with Diabetes and Cardiometabolic Risk Factors in a Community-Based Cohort.
    Loomis SJ; Chen Y; Sacks DB; Christenson ES; Christenson RH; Rebholz CM; Selvin E
    Clin Chem; 2017 May; 63(5):980-989. PubMed ID: 28280052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Soluble Forms and Ligands of the Receptor for Advanced Glycation End-Products in Patients with Acute Respiratory Distress Syndrome: An Observational Prospective Study.
    Jabaudon M; Blondonnet R; Roszyk L; Pereira B; Guérin R; Perbet S; Cayot S; Bouvier D; Blanchon L; Sapin V; Constantin JM
    PLoS One; 2015; 10(8):e0135857. PubMed ID: 26274928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Could AGE/RAGE-Related Oxidative Homeostasis Dysregulation Enhance Susceptibility to Pathogenesis of Cardio-Metabolic Complications in Childhood Obesity?
    Corica D; Aversa T; Ruggeri RM; Cristani M; Alibrandi A; Pepe G; De Luca F; Wasniewska M
    Front Endocrinol (Lausanne); 2019; 10():426. PubMed ID: 31316471
    [No Abstract]   [Full Text] [Related]  

  • 40. Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD).
    Leonardis D; Basta G; Mallamaci F; Cutrupi S; Pizzini P; Tripepi R; Tripepi G; De Caterina R; Zoccali C
    Nutr Metab Cardiovasc Dis; 2012 Sep; 22(9):748-55. PubMed ID: 21470837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.